Home » Topics » Dermatologic, BioWorld Science

Dermatologic, BioWorld Science
RSS

Phase II study of KHK-4083 in atopic dermatitis meets primary endpoint

Feb. 19, 2021

vTv initiates phase I study of PDE4 inhibitor HPP-737 for psoriasis

Feb. 18, 2021

Phase III studies show superiority of topical tirbanibulin to vehicle in actinic keratosis

Feb. 15, 2021

InflaRx presents data from phase IIb SHINE study of vilobelimab

Feb. 12, 2021

BenevolentAI begins first-in-human trial of BEN-2293 for atopic dermatitis

Feb. 12, 2021

Morphine itch comes from neurons, not mast cells

Feb. 9, 2021

China's NMPA accepts Kintor's IND for topical AR degrader GT-20029

Feb. 4, 2021

Akari announces development of its second clinical candidate, votucalis

Feb. 3, 2021

Topline data from pivotal DERMIS-1 and -2 studies of ARQ-151 in plaque psoriasis

Feb. 2, 2021

PF-06826647 is safe and significantly improves disease activity in subjects with plaque psoriasis

Jan. 29, 2021

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...